These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16416145)

  • 1. The market in diabetes.
    Hauber A; Gale EA
    Diabetologia; 2006 Feb; 49(2):247-52. PubMed ID: 16416145
    [No Abstract]   [Full Text] [Related]  

  • 2. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 3. Pfizer dumps Exubera.
    Mack GS
    Nat Biotechnol; 2007 Dec; 25(12):1331-2. PubMed ID: 18066009
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-marketing studies of new insulins: sales or science?
    Gale EA
    BMJ; 2012 Jun; 344():e3974. PubMed ID: 22692652
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of insulin pen devices on the management of diabetes mellitus.
    Meece J
    Am J Health Syst Pharm; 2008 Jun; 65(11):1076-82. PubMed ID: 18499883
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-marketing observational trials and catastrophic health expenditure.
    Yudkin JS
    BMJ; 2012 Jun; 344():e3987. PubMed ID: 22692653
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?
    English P
    Br J Hosp Med (Lond); 2013 Apr; 74(4):192-7. PubMed ID: 23571388
    [No Abstract]   [Full Text] [Related]  

  • 8. Type 2 diabetes market.
    Gershell L
    Nat Rev Drug Discov; 2005 May; 4(5):367-8. PubMed ID: 15902771
    [No Abstract]   [Full Text] [Related]  

  • 9. How small changes led to big profits for insulin manufacturers.
    Cohen D; Carter P
    BMJ; 2010 Dec; 341():c7139. PubMed ID: 21159773
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparing insulin vials to pens--comparison of charges, not healthcare benefits.
    Thethi TK
    J Med Econ; 2013 Oct; 16(10):1228-30. PubMed ID: 23926888
    [No Abstract]   [Full Text] [Related]  

  • 11. Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
    Lynch PM; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
    Am J Manag Care; 2010; 16(12):892-6. PubMed ID: 21348559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patient's opinion of unmet need.
    Hernandez M; Mehr SR
    Am J Manag Care; 2014 May; 20(8 Spec No.):E16. PubMed ID: 25617936
    [No Abstract]   [Full Text] [Related]  

  • 13. The Insulin Boom. WHY THE COST OF THIS LIFESAVING DRUG IS REACHING NEW HEIGHTS.
    Tsai A
    Diabetes Forecast; 2016; 69(2):32-7. PubMed ID: 27048046
    [No Abstract]   [Full Text] [Related]  

  • 14. [What is new in the treatment of diabetes mellitus?].
    Gain T
    Krankenpfl J; 2000 Oct; 38(9-10):328-31. PubMed ID: 11194350
    [No Abstract]   [Full Text] [Related]  

  • 15. Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option.
    Lipska KJ; Hirsch IB; Riddle MC
    JAMA; 2017 Jul; 318(1):23-24. PubMed ID: 28604935
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of patients with diabetes mellitus by means of inhaled insulin].
    Simsek S; de Galan BE; Tack CJ; Heine RJ
    Ned Tijdschr Geneeskd; 2006 Apr; 150(15):829-32. PubMed ID: 16676511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whither inhaled insulin?
    Young B
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):413. PubMed ID: 16932324
    [No Abstract]   [Full Text] [Related]  

  • 18. Rising Costs of Drug/Insulin Treatment for Diabetes: A Perspective from India.
    Misra A; Mukherjee R; Luthra A; Singh P
    Diabetes Technol Ther; 2017 Dec; 19(12):693-698. PubMed ID: 29090974
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypoglycaemia, analogue insulins; prescribing cost or quality of life?
    Hitman GA
    Diabet Med; 2012 Mar; 29(3):289. PubMed ID: 22364579
    [No Abstract]   [Full Text] [Related]  

  • 20. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.